NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rifaximin-α for the maintenance of remission from episodes of hepatic encephalopathy

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Norgine (rifaximin)	Allied Health Professionals Federation
	Board of Community Health Councils in
Patient/carer groups	Wales
Afiya Trust	 British National Formulary
Action on Hepatitis C	Care Quality Commission
Addaction	 Commissioning Support Appraisals
Alliance	Service
Black Health Agency	Department of Health, Social Services
British Liver Trust	and Public Safety for Northern Ireland
Chinese National Healthy Living	Healthcare Improvement Scotland
Centre	Medicines and Healthcare products
Counsel and Care	Regulatory Agency
Drugs action	National Association of Primary Care National Pharmacy Association
Drugsscope Drugsscop	National Pharmacy Association
Equalities National Council	NHS AllianceNHS Commercial Medicines Unit
Hepatitis A -Z Hepatitis B Foundation III	NII 10 0 () ()
Hepatitis B Foundation UKHepatitis C Trust	NHS Confederation Public Health Wales NHS Trust
Hepatitis C Trust Muslim Council of Britain	Scottish Medicines Consortium
Muslim Health Network	Scottisti Medicines Consortiani
National Hepatitis C Network	Possible comparator manufacturer(s)
South Asian Health Foundation	Abbott laboratories (lactulose)
Specialised Healthcare Alliance	Actavis UK (lactulose)
The PBC Foundation	Amdipharm (neomycin)
Youth Net	Arrow generics (lactulose)
- 100011100	Co-Pharma (lactulose)
Professional groups	Intrapharm laboratories (lactulose)
Association of Medical Microbiologists	Lloyds pharmacy (lactulose)
Association of Nurses in Substance	Mylan (lactulose)
Abuse	Novartis (lactulose)
British Association for Services to the	Rusco (lactulose)
Elderly	Sandoz UK (lactulose)
British Association for the Study of the Liver	Teva UK (lactulose, neomycin)

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of rifaximin- α for the maintenance of remission from episodes of hepatic encephalopathy

Issue date: October 2012 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 British Association for the Study of the Liver Nurses Forum British Geriatrics Society British Infection Association British Liver Nurses Forum British Society of Gastroenterology British Viral Hepatitis Group Health Protection Agency Hepatitis Nurse Specialist Forum Infection Control Nurses Association National Pharmacy Association Royal College of General Practitioners Royal College of Pathologists 	Relevant research groups CORE - Digestive Disorders Foundation Foundation for Liver Research MRC Clinical Trials Unit National Institute of Health Research Research Institute for the Care of Older People Evidence Review Group National Institute for Health Research Health Technology Assessment Programme Peninsula Technology Assessment Group (PenTAG)
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for General Microbiology UK Clinical Virology Network United Kingdom Clinical Pharmacy Association 	 Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups None
 Others Bournemouth & Poole, and Dorset PCT Cluster Cwm Taf Health Board Department of Health Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: October 2012 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.